Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biocept Inc BIOCQ

Healthcare Biotechnology
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular... see more

Recent & Breaking News (GREY:BIOCQ)

Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer

Business Wire February 16, 2022

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Business Wire February 10, 2022

Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant

Business Wire January 21, 2022

Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10

Business Wire January 4, 2022

Biocept's CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Business Wire December 9, 2021

Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression

PR Newswire November 22, 2021

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Business Wire November 22, 2021

Biocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer

Business Wire November 18, 2021

Biocept Reports Third Quarter 2021 Financial Results

Business Wire November 15, 2021

Study Shows Biocept's Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations

Business Wire November 9, 2021

Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021

Business Wire November 8, 2021

Biocept to Present at the LD Micro Main Event on October 13

Business Wire October 6, 2021

Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic

Business Wire September 22, 2021

Biocept Invites You to Join Us at the Benzinga Healthcare Small Cap Conference

Newsfile September 22, 2021

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Business Wire September 21, 2021

Biocept to Present at Four Virtual Investor Conferences in September

Business Wire September 7, 2021

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 31, 2021

Biocept's CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Business Wire August 19, 2021

Biocept Reports Second Quarter 2021 Financial Results

Business Wire August 16, 2021

Biocept Launches Liquid Biopsy Test for NRAS Mutations

PR Newswire September 5, 2017